Tag: Tacrine

Over 8,000 patients received tacrine in clinical trials before its 1993 FDA approval. What is Cognex known for? Primarily, it was the brand name for tacrine, the very first medication used to treat mild to moderate dementia of the Alzheimer's type. Despite being a pioneer in Alzheimer's treatment, its history is marked by significant side effects, which led to its discontinuation.

In clinical trials, approximately one-third of patients treated with tacrine, the active ingredient in Cognex, experienced reversible liver damage. For those interested in **what are the side effects of Cognex**, this serious issue, alongside other adverse reactions, ultimately led to the medication being withdrawn from the market.

Cognex (tacrine) was the first drug approved by the FDA for the treatment of mild-to-moderate dementia of the Alzheimer's type. This milestone drug, introduced in 1993, served as a foundational but flawed treatment, eventually withdrawn from the market due to significant safety concerns, primarily liver toxicity.

Cognex (tacrine) was the first drug approved by the FDA for the treatment of Alzheimer's disease, but it has since been discontinued. Originally indicated for mild-to-moderate dementia, the medication was withdrawn due to significant side effects, particularly liver toxicity, which led to its replacement by newer, safer treatments.

Approved by the FDA in 1993, tacrine was the first cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease [1.2.3, 1.4.4]. This article explores the question, 'What is tacrine used for?', its mechanism, and its place in medical history.